ML18282A088

From kanterella
Jump to navigation Jump to search

Daher - Supplemental Information for the Review of the Model No. DN30 Package
ML18282A088
Person / Time
Site: 07109362
Issue date: 09/10/2018
From: Hilbert F, Van Wijk Y
Daher Nuclear Technologies GmbH
To: Saverot P M
Document Control Desk, Office of Nuclear Material Safety and Safeguards
Shared Package
ML18282A087 List:
References
EPID L-2018-NEW-0003
Download: ML18282A088 (1)


Text

DAHER NUCLEAR TECHNOLOGIES GmbH, Margarete-von-Wrangell-Strae 7, 63457 Hanau, Germany Telefon: +49 (0)6181 501-0, Telefax: +49 (0)6181 57 36 92, E-Mail: info.nuclear-technologies@daher.com, Internet: www.daher.com Sitz: Hanau, RG: Hanau HR B 4428, USt-Id-Nr. DE113574961, Gerichtsstand: Hanau, Geschftsführer: Olaf Oldiges Bankverbindung: Societe Generale Frankfurt (BLZ 512 108 00), Konto: 1095013031, SWIFT: SOGEDEFF, IBAN: DE 45 5121 0800 1095 0130 31 Auftrge werden aufgrund unserer Allgemeinen Geschftsbedingungen übernommen. Diese stehen Ihnen auf Wunsch zur Verfügung SV-0432/05-F 1/1 DAHER NUCLEAR TECHNOLOGIES GmbH, Postbox 1365, 63514 Rodenbach Mr. Pierre M. Saverot Project Manager, Spent Fuel Licensing Branch Division of Spent Fuel Management Office of Nuclear Material Safety and Safeguards U.S. Nuclear Regulatory Commission Two White Flint North - Mail Stop T4-B34 11545 Rockville Pike Rockville, MD 20852-2738 USA Ihre Zeichen / Nachricht vom Your ref. / message Docket No. 71.9362 EPID No. L-2018-NEW-0003 Unser Zeichen / Nachricht vom Our ref. / message 0023-SVK-2018-015 Telefon/Fax/E-Mail +49 (0)6181 501 353 +49 (0)6181 501 266 y.vanwijk@daher.com Hanau, 09.10.2018

Subject:

Supplemental information for the review of the model no. DN30 package

Dear Mr. Saverot,

This letter is in response to your request for supplemental information (RSI, reference Docket No. 71-9362, EPID No. L-2018-NEW-0003). RSI Provide the dose rates in the seal regions and the foam in the DN30 package. In order to assess the cumulative radiation effects on polymer-based materials such as the seals and foams in the DN30 package, the dose rates at these regions are needed. This information is required to determine compliance with 10 CFR 71.43 (d) and 71.47(a). The internal dose rates in the DN30 package are provided in proprietary technical note 0023-BBR-2018-004 attached to this letter. We will also take the observations on Criticality Evaluation and Operating Procedures into account and will prepare revised documentation to answer these points. Sincerely,